AstraZeneca (AZN) Tops Q3 EPS by 2c
Get Alerts AZN Hot Sheet
Join SI Premium – FREE
AstraZeneca (NYSE: AZN) reported Q3 EPS of $1.12, $0.02 better than the analyst estimate of $1.10. Revenue for the quarter came in at $6.23 billion versus the consensus estimate of $5.99 billion.
Updated Guidance
- Total Revenue A low to mid single-digit percentage decline
- Core EPS Towards the favourable end of a low to mid teens percentage decline
For earnings history and earnings-related data on AstraZeneca (AZN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novavax (NVAX) stock soars 120% as Sanofi deal 'kicks off a new chapter'
- Sweetgreen (SG) stock surges on revenue beat
- Xponential Fitness (XPOF) removes Anthony Geisler from his duties and suspended him indefinitely as CEO
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!